Phaseline

Companies › Tyligand Pharmaceuticals (Suzhou)

Tyligand Pharmaceuticals (Suzhou): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TSN1611
KRAS G12D inhibitor
KRASPhase 1Malignant NeoplasmApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06385925TSN1611Phase 1Malignant NeoplasmOncologyApr 2027

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.